^
Association details:
| Biomarker: | FGFR2-POC1B fusion |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Lytgobi (futibatinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Futibatinib, an irreversible FGFR1–4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study
Published date:
09/22/2021
Excerpt:
Among patients with CCA who received futibatinib 20 mg QD (n = 64)...The responders included 1 patient with extrahepatic CCA harboring an FGFR2-POC1B fusion (mDOR, 3.5 months)...FGFR2 p.C383R mutation (n = 1), or an FGFR2 p.W290C mutation (n = 1; Supplementary Table S2)....The PFS of the patients with the FGFR2 p.C383R and p.W290C mutations were 9.2 and 8.9 months, respectively.
DOI:
10.1158/2159-8290.CD-21-0697
Trial ID:
